Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.10.0.1
Commitments and Contingencies (Details Textual)
1 Months Ended
Jul. 09, 2015
USD ($)
Sep. 12, 2013
USD ($)
Feb. 21, 2017
USD ($)
Jun. 17, 2016
USD ($)
Feb. 15, 1999
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2018
ft²
Jul. 06, 2016
ft²
Commitments and Contingencies [Line Items]                  
Area of Land | ft²                 2,300
Lease Expiration Period         12 years        
Payment of annual fee   $ 30,000              
License [Member]                  
Commitments and Contingencies [Line Items]                  
Cost of Goods and Services Sold   $ 50,000   $ 15,000 $ 12,500        
Subsequent Event [Member]                  
Commitments and Contingencies [Line Items]                  
Operating Leases, Future Minimum Payments Due           $ 144,000 $ 86,000    
Minimum [Member] | License [Member]                  
Commitments and Contingencies [Line Items]                  
Cost of Goods and Services Sold       5,000          
Maximum [Member] | License [Member]                  
Commitments and Contingencies [Line Items]                  
Cost of Goods and Services Sold       $ 20,000          
New Valeant Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Revenue Recognition, Milestone Method, Description     the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field.            
Proceeds From Upfront Payment     $ 4,000,000            
Revenue Recognition, Milestone Method, Revenue Recognized     $ 99,000,000            
Licensor [Member]                  
Commitments and Contingencies [Line Items]                  
Area of Land | ft²               4,516  
Valeant Pharmaceuticals International Inc [Member] | Licensing Agreements [Member]                  
Commitments and Contingencies [Line Items]                  
Payments to Acquire Intangible Assets $ 1,000,000                
Proceeds from Sale of Intangible Assets $ 32,500,000